Managing Director Kiran Mazumdar-Shaw, BIOCON
Photographer-Namas Bhojani/Bloomberg
Rapid commercialization of Alzumab “will be transformational for us,” said Kiran Mazumdar-Shaw, chairman and managing director of Biocon Ltd.
Managing Director Kiran Mazumdar-Shaw, is seeking a partner to help with expertise and funding for the tests needed for approval in the U.S., she said in an interview. Biocon plans to file for permission in the year ending March to sell in the North American nation, and aims to start marketing Alzumab in that country two to three years later, she said.
Alzumab would provide a novel therapy for a plaque-causing form of the immune disorder that would compete with best-selling products from Johnson & Johnson, AbbVie Inc. and Pfizer Inc. (PFE) The biologic psoriasis treatment, made from living cells, will help Biocon enter a market that it estimates will be valued at $8 billion by 2016.
READ ALL AT
http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5630
Itolizumab (Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon. It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.[1] A double blind, placebo controlled, phase III treat –Plaq study of Itolizumab, successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo.[2] Biocon has received marketing authorization for the drug from the Drugs Controller General of India (DCGI).[3]
- http://www.biocon.com/docs/PR_080113.pdf?subLink=news
- http://www.thehindubusinessline.com/companies/article2789996.ece
- http://www.pharmabiz.com/NewsDetails.aspx?aid=73075&sid=2

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

Reblogged this on Vijaya Shastry Ph.D Physical Chemistry.
LikeLike
Reblogged this on My Blog on Medicinal Chemistry.
LikeLike
Reblogged this on GREEN MED CHEMISTRY.
LikeLike